Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region

“…B-cell neoplasms include diseases, such as non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and chronic lymphoblastic leukemia (CLL) [ 1 ]. These diseases originate in the lymphatic system, and relevant treatments include chemotherapy, with or without immunotherapy, stem cell transplantation, and novel targeted therapies [ 1 – 3 ]. Patients with incurable B-cell neoplasms that do not require immediate, active treatment are sometimes managed with watch and wait (WAW) follow-ups.…”

“…These patients, and patients in remission after treatment are routinely followed by the attending physician. Clinical guidelines exist for assessing survivors of hematological cancer during follow-up, but the guidelines are inconsistent [ 1 – 3 ]. The follow-up interval and the total post-treatment follow-up time for patients with B-cell neoplasms depend on the specific diagnosis and whether the patient has curable, aggressive lymphoma or chronic, incurable B-cell malignancies, such as indolent lymphoma or CLL.…”

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

“…Representing an example of this collaboration, in the case of chronic lymphocytic leukemia (CLL), the European Research Initiative on CLL—which is also the corresponding EHA Working Group on CLL—has recently endorsed the ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up for CLL released on October 19, 2020, in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development. 1 , 2 …”

Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle

“…From the clinical point of view, combination of significant IgG hypogammaglobulinaemia (the arbitrary cut‐off is usually set to ≤ 5g/l) and repeated or severe bacterial infections represents a generally accepted indication for Ig replacement therapy 15,16 in the form of intravenous infusion (IVIG) or more recently, subcutaneous injection (SCIG) which is more cost‐effective, more convenient for the patient and yields comparable results 16,17 …”